更新于：2024-11-01

Chlorhexidine Hydrochloride

盐酸氯己定

更新于：2024-11-01

概要

概要

基本信息

药物类型

小分子化药

别名

Chlorhexidine hydrochloride (JP17/USP)、CHX、洗必泰

+ [3]

靶点-

作用机制

细胞膜功能抑制剂

治疗领域-

在研适应症-

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C22H31Cl3N10

InChIKeyAVRXPIQGQAHQTQ-UHFFFAOYSA-N

CAS号3697-42-5

关联

390

项与盐酸氯己定相关的临床试验

IRCT20240221061066N1 / Suspended临床4期IIT

Investigation of antimicrobial effect of green tea and chlorhexidine mouthwashes on the frequency of Streptococcus mutans strains in children with removable orthodontic appliances: a randomized clinical trial study

开始日期2024-09-22

申办/合作机构-

NCT06541145 / RecruitingN/AIIT

Impact of Bacterial Decolonization on Bacterial Burden Within Maternal-infant Dyads

The goal of this study is to measure bacterial burden, specifically Staph aureus, and how it spreads between mothers and their infants. Researchers will evaluate if the amount of bacteria on their skin remains the same after mothers use a skin antisepsis treatment prior to delivering their infants. The investigators also aim to assess participant interest in and compliance with skin antisepsis treatments. The hypothesis is that increased maternal interest will align with increased treatment compliance.

开始日期2024-08-21

申办/合作机构

Duke University

[+1]

CTRI/2024/05/067879 / Not yet recruiting临床3期IIT

A Comparative Evaluation for the efficacy of Chlorhexidine Gel AndKhadir (Acacia catechu) Gel as an adjunct to Scaling & Root Planing, in Chronic Periodontitis cases: A clinical study - NIL

开始日期2024-07-20

申办/合作机构-

100 项与盐酸氯己定相关的临床结果

登录后查看更多信息

100 项与盐酸氯己定相关的转化医学

登录后查看更多信息

100 项与盐酸氯己定相关的专利（医药）

登录后查看更多信息

9,908

项与盐酸氯己定相关的文献（医药）

2024-12-31·Virulence

Genetic, virulence, and antimicrobial resistance characteristics associated with distinct morphotypes in ST11 carbapenem-resistant Klebsiella pneumoniae

Article

作者: Xiong, Luying ; Wang, Yuan ; Lu, Ping ; Chi, Xiaohui ; Shen, Ping ; Chen, Tao ; Xiao, Yonghong ; Chen, Yunbo ; Wang, Xueting ; Luo, Qixia

ST11 is the most common lineage among carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in Asia. Diverse morphotypes resulting from genetic mutations are associated with significant differences in microbial characteristics among K. pneumoniae isolates. Here, we investigated the genetic determinants and critical characteristics associated with distinct morphotypes of ST11 CRKP. An ST11-KL47 CRKP isolate carrying a pLVPK-like virulence plasmid was isolated from a patient with a bloodstream infection; the isolate had the "mcsw" morphotype. Two distinct morphotypes ("ntrd" and "msdw") were derived from this strain during in vitro passage. Whole genome sequencing was used to identify mutations that cause the distinct morphotypes of ST11 CRKP. Transmission electron microscopy, antimicrobial susceptibility tests, growth assays, biofilm formation, virulence assays, membrane permeability assays, and RNA-seq analysis were used to investigate the specific characteristics associated with different morphotypes of ST11 CRKP. Compared with the parental mcsw morphotype, the ntrd morphotype resulted from mutation of genes involved in capsular polysaccharide biosynthesis (wza, wzc, and wbaP), a result validated by gene knockout experiments. This morphotype showed capsule deficiency and lower virulence potential, but higher biofilm production. By contrast, the msdw morphotype displayed competition deficiency and increased susceptibility to chlorhexidine and polymyxin B. Further analyses indicated that these characteristics were caused by interruption of the sigma factor gene rpoN by insertion mutations and deletion of the rpoN gene, which attenuated membrane integrity presumably by downregulating the phage shock protein operon. These data expand current understanding of genetic, virulence, and antimicrobial resistance characteristics associated with distinct morphotypes in ST11 CRKP.

2024-12-31·Journal of oral microbiology

The effects of nitrate on the oral microbiome: a systematic review investigating prebiotic potential

Review

作者: Rosier, Bob T ; Henriquez, Fiona L ; Burleigh, Mia C ; Moran, Siobhan P

Background:

Nitrate (NO₃^-) has been suggested as a prebiotic for oral health. Evidence indicates dietary nitrate and nitrate supplements can increase the proportion of bacterial genera associated with positive oral health whilst reducing bacteria implicated in oral disease(s). In contrast, chlorhexidine-containing mouthwashes, which are commonly used to treat oral infections, promote dysbiosis of the natural microflora and may induce antimicrobial resistance.

Methods:

A systematic review of the literature was undertaken, surrounding the effects of nitrate on the oral microbiota.

Results:

Overall, n = 12 in vivo and in vitro studies found acute and chronic nitrate exposure increased (representatives of) health-associated Neisseria and Rothia (67% and 58% of studies, respectively) whilst reducing periodontal disease-associated Prevotella (33%). Additionally, caries-associated Veillonella and Streptococcus decreased (25% for both genera). Nitrate also altered oral microbiome metabolism, causing an increase in pH levels (n = 5), which is beneficial to limit caries development. Secondary findings highlighted the benefits of nitrate for systemic health (n = 5).

Conclusions:

More clinical trials are required to confirm the impact of nitrate on oral communities. However, these findings support the hypothesis that nitrate could be used as an oral health prebiotic. Future studies should investigate whether chlorhexidine-containing mouthwashes could be replaced or complemented by a nitrate-rich diet or nitrate supplementation.

2024-12-31·Journal of Oral Microbiology

Silica nanoparticles containing nano-silver and chlorhexidine to suppress Porphyromonas gingivalis biofilm and modulate multispecies biofilms toward healthy tendency

Article

作者: Liu, Fei ; Fang, Lixin ; Wang, Suping ; Cai, Yingchun ; Zhang, Yishuang ; Zheng, Hao ; Zhou, Wen ; Cheng, Lei ; Cheng, Long ; Wang, Yiyi ; Qin, Lu

Objectives:

This research first investigated the effect of mesoporous silica nanoparticles (nMS) carrying chlorhexidine and silver (nMS-nAg-Chx) on periodontitis-related biofilms. This study aimed to investigate (1) the antibacterial activity on Porphyromonas gingivalis (P. gingivalis) biofilm; (2) the suppressing effect on virulence of P. gingivalis biofilm; (3) the regulating effect on periodontitis-related multispecies biofilm.

Methods:

Silver nanoparticles (nAg) and chlorhexidine (Chx) were co-loaded into nMS to form nMS-nAg-Chx. Inhibitory zone test and minimum inhibitory concentration (MIC) against P. gingivalis were tested. Growth curves, crystal violet (CV) staining, live/dead staining and scanning electron microscopy (SEM) observation were performed. Biofilm virulence was assessed. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and Quantitative Real Time-PCR (qPCR) were performed to validate the activity and composition changes of multispecies biofilm (P. gingivalis, Streptococcus gordonii and Streptococcus sanguinis).

Results:

nMS-nAg-Chx inhibited P. gingivalis biofilm dose-dependently (p<0.05), with MIC of 18.75 µg/mL. There were fewer live bacteria, less biomass and less virulence in nMS-nAg-Chx groups (p<0.05). nMS-nAg-Chx inhibited and modified periodontitis-related biofilms. The proportion of pathogenic bacteria decreased from 16.08 to 1.07% and that of helpful bacteria increased from 82.65 to 94.31% in 25 μg/mL nMS-nAg-Chx group for 72 h.

Conclusions:

nMS-nAg-Chx inhibited P. gingivalis growth, decreased biofilm virulence and modulated periodontitis-related multispecies biofilms toward healthy tendency. pH-sensitive nMS-nAg-Chx inhibit the pathogens and regulate oral microecology, showing great potential in periodontitis adjunctive therapy.

项与盐酸氯己定相关的新闻（医药）

2024-02-01

·Science Daily

Large multicenter clinical trial finds that antiseptic containing iodine reduces surgical-site infections in patients with extremity fractures

A large multicenter clinical trial found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. Researchers believe the results of the study of nearly 8,500 patients across the United States and Canada could prevent thousands of surgical-site infections each year. A large multicenter clinical trial co-led by University of Maryland School of Medicine researchers large multicenter clinical trial co-led by University of Maryland School of Medicine researchers found that an antiseptic containing iodine resulted in about one-quarter fewer post-surgical infections in patients with limb fractures compared to another frequently used skin antiseptic. The results of the study of nearly 8,500 patients across the United States and Canada were published today in the New England Journal of Medicine. The study -- which compared the two most commonly used alcohol-based solutions, one with iodine povacrylex, and the other with chlorhexidine gluconate -- may prompt changes in the type of antiseptic orthopaedic surgeons use to prepare the skin to repair fractures. Researchers saw the benefit in patients with closed, or simple fractures, where the skin remains intact, but not in compound fractures with open wounds, although they noted that using the iodine preparation was not harmful to these open-fracture patients. "Our results suggest that the use of iodine povacrylex in alcohol as a preoperative skin antiseptic could prevent surgical-site infections in thousands of patients with closed fractures each year," said co-principal investigator Gerard Slobogean, MD, MPH, an Associate Professor of Orthopaedics and Director of Clinical Research in the Department of Orthopaedics at the University of Maryland School of Medicine (UMSOM). He is also an orthopaedic trauma surgeon at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center (UMMC). Each year, more than a million Americans suffer a broken bone in the arm, leg, or pelvis that requires surgery, and about 3 percent of these patients develop a surgical-site infection. The source of bacteria could be the patient's skin, the injury environment, or from the hospital. Although some guidelines have favored using chlorhexidine gluconate over other iodine products, there has not been a consensus on the most effective agent. Dr. Slobogean and his colleagues believe that the trial, which included 8,485 patients treated at 25 trauma centers, is the largest randomized clinical trial ever conducted to compare the two antiseptics, which allowed them to detect important differences in infection. They said that the findings may also be relevant to other surgical specialties. More than 6,700 patients who had surgery to treat a closed lower extremity or pelvic fracture and 1,700 patients who had surgery to treat an open fracture participated in the study. The R Adams Cowley Shock Trauma Center and University of Maryland Capital Region Health's (UM Capital) trauma center in Largo, Md., were among more than two dozen trauma centers to enroll patients. UMMC and UM Capital are part of the 11-hospital University of Maryland Medical System (UMMS). "The results of this well-designed study provide some long overdue clarity to orthopaedic trauma surgeons with respect to which commonly used antiseptic skin preparation is more effective when preparing for fracture surgery," said study co-author Todd Jaeblon, DO, an Associate Professor of Orthopaedics at UMSOM who treats patients at UM Capital. Of the 3,205 closed-fracture patients who received 0.7% iodine povacrylex in 74% isopropyl alcohol, 77, or 2.4 percent, developed a surgical-site infection. That compares with 108, or 3.3 percent of the 3,272 patients who received 2% chlorhexidine gluconate in 70% isopropyl alcohol. In patients with open fractures, the number of patients who developed infections was similar between the two antiseptics -- 54 patients, or 6.5 percent of 825 patients in the iodine group, and 60 patients, or 7.3% of the 826 patients in the chlorhexidine group. "Extremity fractures and the challenging surgical-site infections that result from them pose a significant health care burden on our nation," said Mark T. Gladwin, MD, who is the John Z. and Akiko K. Bowers Distinguished Professor and Dean, UMSOM, and Vice President for Medical Affairs, University of Maryland, Baltimore. "This pragmatic trial tested two widely used antiseptics, and its crossover design minimized selection bias. It also enrolled patients from 25 diverse hospitals in the U.S. and Canada, which improved the generalizability of the results; the strength of the study design could serve as a model for other researchers." The PREPARE (Pragmatic Randomized Trial Evaluating Preoperative Alcohol Skin Solutions in Fractured Extremities) trial was jointly led by UMSOM and McMaster University of Hamilton, Ontario. It was funded with $11.2 million from the Patient-Centered Outcomes Research Institute (PCORI), with additional support from the Canadian Institutes of Health Research. "This trial represents a highly successful collaboration between McMaster University, the University of Maryland School of Medicine, and 25 trauma centers across Canada and the United States," said co-principal investigator Sheila Sprague, PhD, an Associate Professor and Research Director at McMaster University. "This multidisciplinary approach allowed us to quickly and efficiently address an important clinical research question that will lead to the prevention of thousands of infections each year. Importantly, our collaborations will continue to grow to address other unanswered questions in orthopaedic trauma surgery." This is the second clinical study co-led by Dr. Slobogean and Dr. Sprague aimed at closing the gaps in the medical literature on the most effective infection-control techniques in orthopaedic surgery. In October 2022, they published the results of the Aqueous-PREP trial in The Lancet. They concluded that the choice of an aqueous antiseptic solution -- either 10% povidone-iodine or 4% chlorhexidine gluconate -- does not alter the risk of surgical-site infection for patients with an open fracture. Both Aqueous-PREP and PREPARE follow a master protocol called PREP-IT (Program of Randomized Trials to Evaluate Preoperative Antiseptic Skin Solutions in Orthopaedic Trauma) to test infection prevention techniques in trials that will provide crucial evidence to help guide surgical practices. This research was supported by the PREP-IT investigators, which includes a network of over 200 physicians, allied health care professionals, trauma patients, and clinical researchers.

临床结果临床研究

2023-12-13

·Business Wire

Ondine Successfully Raised C$4.91 Million to Support Acceleration of Its Commercial Rollout of Nasal Decolonization to Prevent Healthcare-associated Infections

VANCOUVER, Canada--( BUSINESS WIRE )--Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens – bacteria, viruses and fungi – without causing antimicrobial resistance. The company has confirmed that it has more than doubled the number of Steriwave ® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global focus on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine’s photodisinfection technology. The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%, 2 and very poor compliance. 3 Carolyn Cross, CEO of Ondine, commented, "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024.” The five-minute Steriwave nasal decolonization procedure is easy to incorporate into the pre surgery procedures. It is painless and very well received by patients who are often intrigued by the process. There have been no reports of serious side effects as a result of Steriwave usage. Steriwave has been used by more than 150,000 patients, including at Vancouver General Hospital where its use has been associated with a significant reduction in HAIs across major surgeries. 4,5 As well as growing its commercial activities, the company continues to work closely with HCA – the largest hospital group in the United States – to prepare for the Phase 3 trial in circa 14 HCA hospitals as part of its Ondine’s submission to the FDA for approval. The company already has approval for Steriwave in Canada, the UK, the EU, and Mexico. Implementing nasal decolonization prior to major surgery to reduce HAIs is recommended by leading medical bodies, including the World Health Organization, 6 the Society for Healthcare Epidemiology of America (SHEA), 7 and NICE. 8 The nose is the major reservoir of pathogens and the majority of surgical site infections (SSIs) and bloodstream infections have been traced back to bacteria in the patient’s nose. 9 A patient with a surgical site infection (SSI) will, on average, spend 7 to 11 days longer in the hospital, significantly increasing costs and lengthening patients' recovery. 10 While currently focusing on nasal decolonization, Ondine’s patented photodisinfection technology will be developed to prevent and treat a wide variety of topical infections. About Ondine Biomedical Inc. Ondine Biomedical Inc. is a Canadian life science company pioneering the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications. 1 Stone PW. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):417-22. doi: 10.1586/erp.09.53. PMID: 19817525; PMCID: PMC2827870. 2 Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical implications and potential alternatives for the eradication of MRSA. J Antimicrob Chemother . 2015;70(10):2681-2692. doi:10.1093/jac/dkv169 3 Hansen D, Patzke PI, Werfel U, Benner D, Brauksiepe A, Popp W. Success of MRSA eradication in hospital routine: depends on compliance. Infection. 2007 Jun;35(4):260-4. doi: 10.1007/s15010-007-6273-y. Epub 2007 Jul 23. PMID: 17646910. 4 Bryce E, Wong T, Forrester L, Masri B, Jeske D, Barr K, Errico S, Roscoe D. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014 Oct;88(2):89-95. doi: 10.1016/j.jhin.2014.06.017. Epub 2014 Aug 1. Erratum in: J Hosp Infect. 2015 Sep;91(1):93. PMID: 25171975. 5 Moskven E, Banaszek D, Sayre E, Gara A, Bryce E, Wong T, Ailon T, Charest-Morin R, Dea N., Dvorak M, Fisher C, Kwon B, Paquette S, Street J. Effectiveness of prophylactic intranasal photodynamic disinfection therapy and chlorhexidine gluconate body wipes for surgical site infection prophylaxis in adult spine surgery. Can J Surg. 2023 Nov;66(6), E550–E560. https://doi.org/10.1503/cjs.016922 6 World Health Organization. Global Guidelines for the Prevention of Surgical Site Infection. World Health Organization; 2016. Available at: https://www.who.int/publications/i/item/9789241550475 . Accessed December 12, 2023. 7 Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67 8 National Institute for Health and Care Excellence (NICE). NICE Surgical Site Infections: Prevention and Treatment. NICE; 2019. Available at: https://www.nice.org.uk/guidance/ng125 . Accessed December 12, 2023. 9 von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. 2001 Jan 4;344(1):11-6. doi: 10.1056/NEJM200101043440102. PMID: 11136954. 10 Seidelman JL, Mantyh CR, Anderson DJ. Surgical Site Infection Prevention: A Review. JAMA. 2023;329(3):244–252. doi:10.1001/jama.2022.24075

临床3期上市批准

2023-12-05

·GlobeNewswire-Health Care

Teleflex Awarded Peripheral Access Agreement with Premier, Inc.

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex’s Peripheral Access products. Premier has awarded Teleflex a national multi-source agreement for Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines. “Teleflex strives to deliver vascular access products that are designed to benefit both clinicians and patients, while helping to protect against vascular access related complications1-7,” said Lisa Kudlacz, President and General Manager, Teleflex Vascular. “We are pleased to continue to support Premier members with these PICC, Midline and Navigation products. Arrow™ PICCs and Midlines are available in a traditional design or with Arrowg+ard Blue Advance™ Protection Technology that’s proven effective to reduce catheter colonization by the major central line associated blood stream infection (CLABSI) causing pathogens.”2-7 Teleflex, through its Arrow™ Peripheral Access products, has recently refreshed the portfolio to help healthcare providers optimize patient outcomes, reduce catheter colonization of the major central line-associated infections (CLABSI) causing pathogens, and efficiently streamline insertion procedures1-7. The group purchasing agreement includes access to the: Arrow™ VPS Rhythm DLX™ Device capital equipment portfolio for PICC placementsArrow™ PICCs preloaded with the NaviCurve™ StyletArrow™ VPS G4™ Capital Equipment portfolio for PICC placementsTraditional Arrow™ PICCsArrowg+ard Blue Advance™ Antimicrobial/Antithrombogenic PICCsTraditional Arrow™ MidlinesArrowg+ard Blue Advance™ Antimicrobial/Antithrombogenic MidlinesArrow™ Twin Cath™ Peripheral CathetersPeripheral Access accessories Teleflex is committed to supporting vascular access specialists in their efforts to reduce vascular-related complications by offering the world's first antimicrobial and antithrombogenic PICCs and Midlines.3,7 Utilizing Arrowg+ard Blue Advance™ PICCs and Midlines guards against CLABSI-causing pathogens in areas that are clinically out of reach.3,7 This protection lasts while the line is in the patient for at least 30 days.3,7 The next-generation VPS Rhythm™ DLX Device provides real-time catheter tip location information by using the patient’s cardiac electrical activity. The device is also available with an optional integrated ultrasound featuring a Catheter-to-Vessel ratio tool that promotes standardization in vessel measurement. This device works in concert with the Arrow™ PICC preloaded with the NaviCurve™ Stylet, providing innovative tip navigation/location technologies. The VPS Rhythm™ DLX Device with TipTracker™ Technology eliminates the need for a confirmatory x-ray8, helping the clinician insert seamlessly through ultrasound vessel assessment, PICC navigation, to final tip confirmation in the lower third of the superior vena cava.1 Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. About Teleflex IncorporatedTeleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com. Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose. Forward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. References1. D041679 Benchtop Stylet Advancement in a Simulated Use Anatomical Model of NaviCurve™. Product Stylet/PICC Assemblies. Bench testing may not be indicative of clinical performance. 2. In-vitro data on file 2010: AVER-004371 and AVER-004483. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.3. As compared to uncoated PICCs, intravascular ovine model inoculated with Staph aureus: AVAR-000427. No correlation between in-vitro/in-vivo testing methods and clinical outcomes have currently been ascertained.4. Grau D, Clarivet B, Lotthé A, Bommart S, Parer S. Complications with peripherally inserted central catheters (PICCs) used in hospitalized patients and outpatients: a prospective cohort study. Antimicrob Resist Infect Control. 2017;6:18. doi:10.1186/s13756-016-0161-0 5. Moreau N. Preventing PICC complications: whose line is it? Patient Safety Network. December 1, 2012. Accessed January 9, 2023. https://psnet.ahrq.gov/web-mm/preventing-picc-complications-whose-line-it 6. Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. November 2017. Accessed November 9, 2022. https://www.ahrq.gov/hai/pfp/haccost2017-results.html 7. In-vitro data on file 2010: AVER-004371, AVER-004483 and AVAR-000427. No correlation between in vitro/in vivo testing methods and clinical outcomes has currently been ascertained.8. DLX-200-OPM-US: VPS Rhythm™ DLX Operator's Manual. Rx only Contraindication: Clinical assessment of the patient must be completed to ensure no contraindications exist. The Arrowg+ard Blue Advance™ PICC is contraindicated in the following areas: • Patients with known hypersensitivity to chlorhexidine• In presence of device related infections• In presence of previous or current thrombosis in the intended vessel or along the catheterized vessel pathway. No correlation between in vitro/in vivo testing methods and clinical outcomes have currently been ascertained. For complete indications, contraindications, warnings, precautions, and adverse reactions, please refer to each referenced product's full package insert. Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance, Deknatel, LMA, NaviCurve, Pilling, QuikClot, Rüsch, TipTracker, UroLift, VPS Rhythm, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are trademarks or registered trademarks of their respective owners. © 2023 Teleflex Incorporated. All rights reserved. MC-009285 Contact:Teleflex Incorporated:Lawrence KeuschVice President, Investor Relations and Strategy Developmentinvestors.teleflex.com610-948-2836

100 项与盐酸氯己定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01345	-	-	DB00878

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03503370 (CTgov)	临床2期	糖尿病足溃疡	175	Chlorhexidine (Chlorhexidine)	齋範窪淵繭範艱齋顧簾(繭窪製選鬱廠鏇鹽壓顧) = 選憲壓衊蓋憲餘築鹹遞醖積襯衊淵築艱構觸網 (夢糧遞餘夢艱鑰壓製膚, 選餘網壓糧顧選築鹽遞 ~ 糧願衊築憲觸襯窪鏇願) 更多	-	2024-08-09
				Placebo (Placebo)	齋範窪淵繭範艱齋顧簾(繭窪製選鬱廠鏇鹽壓顧) = 選築遞餘襯醖衊蓋蓋繭醖積襯衊淵築艱構觸網 (夢糧遞餘夢艱鑰壓製膚, 淵蓋廠鑰夢餘壓糧製齋 ~ 壓夢選淵積醖壓築築壓) 更多
WCD2023	N/A	-	-	Chlorhexidine Gentle hand wash (Microshield®)	選遞觸繭觸鏇餘壓獵膚(艱築製壓膚繭鹽壓蓋鏇) = 構蓋網簾簾襯糧製選顧衊構醖糧淵獵夢醖衊醖 (獵夢簾齋獵選願鹹選齋 )	-	2023-07-03
				Chlorhexidine Gentle hand wash (Gentle wash)	選遞觸繭觸鏇餘壓獵膚(艱築製壓膚繭鹽壓蓋鏇) = 獵衊鏇齋鏇鏇齋積窪簾衊構醖糧淵獵夢醖衊醖 (獵夢簾齋獵選願鹹選齋 )
NCT03442218 (Pubmed)	N/A	胎膜早破	204	Chlorhexidine solution	醖鏇簾憲繭餘襯餘築鏇(範廠淵繭齋鏇衊窪衊簾) = 鏇鏇範衊簾齋壓網構獵蓋範壓蓋鏇積夢選餘積 (鹽鏇蓋繭蓋膚襯醖觸構 ) 更多	积极	2022-01-17
				Saline solution	醖鏇簾憲繭餘襯餘築鏇(範廠淵繭齋鏇衊窪衊簾) = 鬱鏇襯襯餘壓蓋齋鏇淵蓋範壓蓋鏇積夢選餘積 (鹽鏇蓋繭蓋膚襯醖觸構 ) 更多
NCT01079663 (CTgov)	临床2期	种植体周围炎	60	Chlorhexidine 2.5 mg (Chlorhexidine Chip (Periochip®))	壓壓築夢蓋積糧夢觸選(憲繭製窪選鬱衊醖鹹築) = 顧憲顧蓋積廠膚餘夢願鹽糧廠憲餘鑰網獵鹹廠 (鏇窪製艱觸淵簾遞廠觸, 衊積構構艱遞築膚窪遞 ~ 窪淵繭糧壓顧簾範壓蓋) 更多	-	2021-06-15
				Placebo chip (Placebo Chip)	壓壓築夢蓋積糧夢觸選(憲繭製窪選鬱衊醖鹹築) = 衊壓製淵構艱製淵艱壓鹽糧廠憲餘鑰網獵鹹廠 (鏇窪製艱觸淵簾遞廠觸, 製糧獵範築顧遞膚膚鹹 ~ 壓構衊淵鑰蓋淵餘鏇廠) 更多
NCT02252588 (CLIMB, CTgov)	临床2期	慢性阻塞性肺疾病	44	Placebo+Chlorhexidine (Chlorhexidine)	範觸夢構夢構積鏇鏇選(觸鹹糧鹽憲獵簾淵壓餘) = 願鬱醖齋網廠壓遞網網鑰蓋築夢繭鹹淵襯構蓋 (遞鹽糧製醖醖鬱觸餘壓, 積積範鑰選鏇製鹹壓憲 ~ 獵襯築鏇壓艱範範餘蓋) 更多	-	2020-12-29
				Placebo+Chlorhexidine (Placebo)	範觸夢構夢構積鏇鏇選(觸鹹糧鹽憲獵簾淵壓餘) = 襯鏇範網壓齋廠鏇糧鑰鑰蓋築夢繭鹹淵襯構蓋 (遞鹽糧製醖醖鬱觸餘壓, 齋艱壓獵觸選窪繭憲艱 ~ 夢廠網糧淵遞觸衊醖顧) 更多
NCT03412734 (CTgov)	临床4期	-	94	Chlorhexidine (Chlorhexidine Group)	築選鑰遞襯蓋衊鬱遞獵(獵遞構廠衊選製淵糧積) = 夢齋廠簾衊艱鑰構遞淵遞網鏇蓋範遞鬱窪繭範 (遞範構鬱襯簾鑰積鹽鹹, 願鹽鹹衊顧壓鹹齋廠獵 ~ 窪觸顧範構糧夢鏇廠製) 更多	-	2020-11-18
				Iodine (Iodine Group)	築選鑰遞襯蓋衊鬱遞獵(獵遞構廠衊選製淵糧積) = 築鏇鏇醖網獵構淵鑰網遞網鏇蓋範遞鬱窪繭範 (遞範構鬱襯簾鑰積鹽鹹, 餘願鹹網鹹憲襯願壓衊 ~ 蓋繭餘鏇積夢糧積齋蓋) 更多
STRIPES (Pubmed \| Am J Obstet Gynecol)	N/A	感染	1,356	Sage 2% chlorhexidine cloths	繭醖鑰鑰觸艱觸醖淵夢(齋製糧遞繭獵繭淵築顧) = 衊遞餘淵繭鏇遞簾獵構蓋窪廠淵積衊衊製壓願 (衊膚築醖醖齋築鑰獵獵 )	不佳	2020-07-01
				Sage Comfort Bath fragrance-free cloths	繭醖鑰鑰觸艱觸醖淵夢(齋製糧遞繭獵繭淵築顧) = 觸窪夢糧鑰選糧蓋鏇願蓋窪廠淵積衊衊製壓願 (衊膚築醖醖齋築鑰獵獵 )
NCT04218799 (CTgov)	临床4期	交叉感染	19	Topical Chlorhexidine+Intranasal Mupirocin	鹹選鏇選艱獵築衊遞製(醖壓膚網襯蓋範窪觸憲) = 醖獵築顧積餘鹽鏇選憲積窪顧壓顧鏇遞艱範遞 (壓範鹽衊鑰廠艱衊築餘, 衊淵膚觸夢淵膚艱糧鹽 ~ 網網簾衊醖膚壓齋觸製) 更多	-	2020-04-24
NCT04222699 (CTgov)	临床4期	-	58	Mupirocin calcium ointment, 2%+Topical Chlorhexidine, 4%	醖觸鏇壓網廠願餘鬱積(糧願鬱鏇繭願廠鹽鹹壓) = 製窪廠襯壓鏇鏇窪築積齋簾鑰齋醖淵餘醖襯鏇 (網遞獵窪襯願築憲窪顧, 範簾糧觸醖膚遞膚積觸 ~ 繭積鬱憲夢衊窪鑰憲積) 更多	-	2020-04-14
NCT02223520 (TREAT PARENTS, CTgov)	N/A	金黄色葡萄球菌菌血症 \| 葡萄球菌感染	307	Chlorhexidine+Mupirocin (Mupirocin and Chlorhexidine)	積糧餘築齋襯襯築襯鬱(憲選淵顧齋醖鑰醖壓夢) = 齋餘憲構簾夢願醖衊製齋築憲衊鏇範夢獵蓋淵 (鑰築顧觸願餘簾醖鏇獵, 壓餘蓋網選艱餘範願顧 ~ 廠鬱獵顧蓋構鏇製獵鑰) 更多	-	2020-03-16
				placebo cloths (Placebo Ointment and Placebo Cloths)	積糧餘築齋襯襯築襯鬱(憲選淵顧齋醖鑰醖壓夢) = 網觸顧膚顧獵觸簾築願齋築憲衊鏇範夢獵蓋淵 (鑰築顧觸願餘簾醖鏇獵, 艱觸鹹範鑰蓋繭淵選餘 ~ 選範鹹築鏇艱簾鹹蓋淵) 更多